Usted buscó: antiparkinsonian (Inglés - Maltés)

dose adjustments of antiparkinsonian therapy
aġġustamenti fid-doża tat-terapija kontra l-marda ta’ parkinson

other antiparkinsonian medicinal products:
prodotti mediċinali kontra l- marda ta ’ parkinson oħra:

comtan has no antiparkinsonian activity without levodopa.
comtan m’ għandu l- ebda attività kontra l- marda ta’ parkinson mingħajr levodopa.

you may also use other antiparkinsonian medicines at the same time.
tista ’ tuża wkoll mediċini oħra kontra l- marda tal- parkinson fl - istess ħin.

4 phosphokinase has been reported with the abrupt withdrawal of antiparkinsonian agents.
id- dijanjosi bikrija hija importanti għall - immaniġġjar xieraq ta ’ nms.

the dose of other antiparkinsonian medicines may need to be adjusted when you start taking comtan.
id- doża ta ’ mediċini kontra l- parkinson jista ’ jkollha bżonn tiġi aġġustata meta tibda tieħu comtan.

abrupt discontinuation of both comtan and other antiparkinsonian medicines may result in unwanted side effects.
it - twaqqif f’ daqqa kemm ta ’ comtan kif ukoll tal- mediċini l- oħrajn kontra l- marda ta ’ parkinson jista ’ jwassal għal effetti sekondarji mhux mixtieqa.

the doses of other antiparkinsonian medicinal products may need to be adjusted when entacapone treatment is initiated.
meta tinbeda l-kura b’entacapone, jista’ jkun hemm bżonn ta’ tibdil fid-dożi ta’ prodotti mediċinali oħra ta’ kontra l-marda ta’ parkinson.

in such case, your doctor may need to re- adjust the dosage of your other antiparkinsonian medicines.
it- tabib tiegħek għandu mnejn ikollu bżonn jibdel id- dożi tal- mediċini l- oħra kontra l- marda ta ’ parkinson jekk tieqaf tieħu comtan.

to date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with stalevo therapy.
s’ issa ma kienx hemm indikazzjoni ta ’ interazzjonijiet li ma jippermettux l- użu flimkien ta ’ prodotti mediċinali standard kontra l- marda ta ’ parkinson ma ’ terapija b’ stalevo.

the doses of other antiparkinsonian medicinal products may need to be adjusted when stalevo treatment is substituted for a patient currently not treated with entacapone.
jista jkun hemm bżonn li d-doża ta’ prodotti mediċinali oħrajn kontra l-marda ta’ parkinson tiġi aġġustata meta jkun hemm sostituzzjoni ta’ kura b’stalevo għall-pazjent li bħalissa mhux qed jiġi kkurat b’entacapone.

particularly d2 receptor antagonists should be carried out with caution, and the patient carefully observed for loss of antiparkinsonian effect or worsening of parkinsonian symptoms.
partikolarment antagonisti tar- riċetturi d2, għandha ssir b’ kawtela, u l- pazjent għandu jiġi sorveljat għat- telf ta ’ l- effett kontra l- marda ta ’ parkinson jew rkadar tas- sintomi tal- marda ta ’ parkinson.

if you suddenly stop taking levodopa/carbidopa/entacapone orion and other antiparkinsonian medicines it may result in unwanted side effects.
jekk twaqqaf it-teħid ta’ levodopa/carbidopa/entacapone orion u ta’ mediċini kontra l-marda ta’ parkinson oħra f’daqqa, dan jista’ jirriżulta f’effetti sekondarji mhux mixtieqa.

if ongentys is discontinued it is necessary to adjust the dosing of the other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the symptoms.
jekk ongentys jitwaqqaf, ikun meħtieġ li jiġi aġġustat id-dożaġġ ta’ trattamenti oħrajn ta’ kontra l- marda ta’ parkinson, speċjalment levodopa, sabiex jinkiseb livell suffiċjenti ta’ kontroll tas-sintomi.

a syndrome resembling the neuroleptic malignant syndrome including muscular rigidity, elevated body temperature, mental changes and increased serum creatine phosphokinase has been reported with the abrupt withdrawal of antiparkinsonian agents.
sindrome li jixbaħ is-sindrome newrolettiku malinn inkluż riġidità fil-muskoli, temperatura tal-ġisem elevata, bidliet mentali u żjieda tal-creatine phosphokinase fis-serum kien irrappurtat mal-waqfien f’daqqa ta’ sustanzi kontra l-marda ta’ parkinson.

if entacapone treatment is discontinued, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms.
jekk il-kura b’entacapone titwaqqaf, ikun hemm bżonn li jinbidel id-dożaġġ ta’ trattamenti oħra għal kontra l-marda ta’ parkinson, speċjalment ta’ levodopa, sabiex jintlaħaq livell suffiċjenti ta’ kontroll tas-sintomi ta’ parkinson.

concomitant administration of antipsychotics with dopamine receptor-blocking properties, particularly d2 receptor antagonists should be carried out with caution, and the patient carefully observed for loss of antiparkinsonian effect or worsening of parkinsonian symptoms.
l-għotja fl-istess waqt ta’ antipsikotiċi bi proprjetajiet li jimblukkaw ir-riċetturi ta’ dopamine, partikolarment antagonisti tar-riċetturi d2, għandha ssir b’kawtela, u l-pazjent għandu jiġi sorveljat b’attenzjoni għat-telf tal-effett kontra l-marda ta’ parkinson jew irkadar tas-sintomi tal-marda ta’ parkinson.

other antiparkinsonian medicinal products: to date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with levodopa/carbidopa/entacapone orion therapy.
prodotti mediċinali kontra l-marda ta’ parkinson oħra: s’issa ma kienx hemm indikazzjoni ta’ interazzjonijiet li ma jippermettux l-użu flimkien ta’ prodotti mediċinali standard kontra l-marda ta’ parkinson ma’ terapija b’levodopa/carbidopa/entacapone orion.

discontinuation of corbilta therapy: if corbilta treatment (levodopa/carbidopa/entacapone) is discontinued and the patient is transferred to levodopa/ddc inhibitor therapy without entacapone, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms.
twaqqif ta’ terapija b’corbilta: jekk kura b’corbilta (levodopa/carbidopa/entacapone) titwaqqaf u l-pazjent jiġi trasferit għal terapija b’levodopa/inibitur ta’ ddc mingħajr entacapone, huwa neċessarju li d-dożaġġ ta’ kull kura oħra kontra l-marda ta’ parkinson jiġi aġġustat, speċjalment levodopa, sabiex jintlaħaq livell ta’ kontroll suffiċjenti tas-sintomi tal-marda ta’ parkinson.